Clinical Trial

Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management

Study acronym: OEUVRE
Recruiting
View on ClinicalTrials.gov →
Summary
Treatment for cancers of the pharyngolarynx is mutilating, with major consequences for patients' lives in terms of physical and functional after-effects. The psycho-social consequences are also significant, notably the metamorphosis of identity linked to the disease and its treatment, which alters the patient's self-image. Initial feedback from patients who have been able to benefit from adapted oncoesthetics (OEA) is overwhelmingly positive. This study will assess the feasibility of oncoesthetics and describe any obstacles.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-05; most recent amendment 2026-03-11.
Status change: Not Yet Recruiting → Recruiting 2026-03-11
Trial Details
NCT Number NCT06959810
Lead Sponsor Centre Francois Baclesse
Collaborators: Fondation de France, Groupement Interrégional de Recherche Clinique et d'Innovation
Conditions Oncology, Aerodigestive Tract Cancer, Suportive Care
Enrollment 55 participants
Start Date 2025-10-24
Primary Completion 2027-09-15 (estimated)
Study Completion 2028-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-12